AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26211002 — intervention group
Group type: COMPARATOR
Intervention: Sa-am acupuncture (Group B)
Number of subjects: 150
Study 24461665 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN)
Number of subjects: 600
Study 24461665 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 600
Study 21118161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 294
Study 21118161 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 294
Study 21118161 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 294
Study 18770084 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management interventions with religious activities (engagers n = 34)
Number of subjects: 184
Study 18770084 — intervention group
Group type: COMPARATOR
Intervention: Contingency management interventions without religious activities (non-engagers n = 150)
Number of subjects: 184
Study 16176203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose level at 16 mmol/l for 3 hours)
Number of subjects: 7
Study 16176203 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemia (blood glucose level at 5 mmol/l for 3 hours)
Number of subjects: 7
Study 12591750 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg BID
Number of subjects: 360
Study 12591750 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 10 mg BID
Number of subjects: 360
Study 12591750 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study 10536326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-detachable snare ligation
Number of subjects: 103
Study 10536326 — intervention group
Group type: COMPARATOR
Intervention: Multiple band ligation
Number of subjects: 103
Study 8678158 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (4 mg, 2 applications 4 hours apart)
Number of subjects: 200
Study 8678158 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 hours, 2 mU/min)
Number of subjects: 200
Study 1676302 — intervention group
Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 100
Study 1676302 — intervention group
Group type: COMPARATOR
Intervention: No Drainage
Number of subjects: 100
Study 6352601 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin at 8 g/day
Number of subjects: 79
Study 6352601 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin at 12 g/day
Number of subjects: 79
Study 30896645 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 38
Study 30896645 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength training
Number of subjects: 38
Study 28649868 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) intervention, Recent Traumatic Episode Protocol (R-TEP) provided within three months of the traumatic event.
Number of subjects: 529
Study 28649868 — intervention group
Group type: COMPARATOR
Intervention: Control group analogue (waitlist-like control group)
Number of subjects: 529
Study 27231116 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized insoles with an added strip of the same material at the site of greatest plantar pressure (n=14)
Number of subjects: 29
Study 27231116 — intervention group
Group type: COMPARATOR
Intervention: Ethylvinylacetate insoles (Podaly®) that were individually heat molded and heat glued (n=13)
Number of subjects: 29
Study 24703486 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic replacement-dose recombinant human leptin (metreleptin)
Number of subjects: 39
Study 24703486 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 39
Study 24703486 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment in vitro
Number of subjects: 39
Study 24703486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22691378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl Plus sutures
Number of subjects: 328
Study 22691378 — intervention group
Group type: COMPARATOR
Intervention: Conventional Vicryl sutures
Number of subjects: 328
Study 19034587 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiatal hernia (HH) group
Number of subjects: 48
Study 19034587 — intervention group
Group type: COMPARATOR
Intervention: Control group (NHH)
Number of subjects: 48
Study 17449890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 46
Study 17449890 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 46
Study 14689162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 75
Study 14689162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 75
Study 14689162 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg diazepam
Number of subjects: 75
Study 14689162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12494613 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 100
Study 12494613 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 100
Study 11368138 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery Doppler screening followed by 100 mg of aspirin daily until the 35th week
Number of subjects: 3317
Study 11368138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Doppler screening and no aspirin treatment)
Number of subjects: 3317
Study 9432046 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim 263 microg/d s.c.
Number of subjects: 90
Study 9432046 — intervention group
Group type: COMPARATOR
Intervention: no growth factor
Number of subjects: 90
Study 8508709 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tetracycline hydrochloride 500 mg four times a day for days 0-14 and metronidazole 500 mg three times a day for days 15-28)
Number of subjects: 26
Study 8508709 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (120 mg four times a day for 8 weeks)
Number of subjects: 26
Study 8508709 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy offered to six patients on bismuth whose ulcers remained unhealed or relapsed early after healing
Number of subjects: 26
Study 8508709 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-negative patients at 18 months
Number of subjects: 26
Study 8508709 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori-positive patients at 18 months
Number of subjects: 26
Study 3729081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal azatadine maleate TDDS
Number of subjects: 20
Study 3729081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral doses of azatadine
Number of subjects: 20
Study 3729081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29783269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen + paracetamol (n = 12)
Number of subjects: 24
Study 29783269 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen + placebo (n = 12)
Number of subjects: 24
Study 27597745 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention targeting intake of whole plant foods
Number of subjects: 136
Study 24523037 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) levels in the top quartile (hsCRP>4.86 mg/L)
Number of subjects: 1244
Study 22088268 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based training
Number of subjects: 3
Study 22088268 — intervention group
Group type: COMPARATOR
Intervention: Time condition
Number of subjects: 3
Study 22088268 — intervention group
Group type: COMPARATOR
Intervention: Repetition condition
Number of subjects: 3
Study 22088268 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency condition (experiment 2)
Number of subjects: 3
Study 21116018 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase and 5α-reductase inhibitor (AI) 500 mg once per day for 8 weeks
Number of subjects: 30
Study 21116018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) 500 mg once per day for 8 weeks
Number of subjects: 30
Study 18182599 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY (at 2, 3, and 4 months or 2 and 4 months)
Number of subjects: 421
Study 18182599 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY (at 2, 4, and 6 months or 2 and 4 months)
Number of subjects: 421
Study 18182599 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY (at 12 months)
Number of subjects: 421
Study 18182599 — intervention group
Group type: COMPARATOR
Intervention: MenC (at 2 and 4 months)
Number of subjects: 421
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625/MPA 2.5
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45/MPA 2.5
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45/MPA 1.5
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.3
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.3/MPA 1.5
Number of subjects: 822
Study 15654581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 15654581 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (all doses combined)
Number of subjects: 822
Study 12877450 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus (inhalation powder)
Number of subjects: 154
Study 12877450 — intervention group
Group type: COMPARATOR
Intervention: MDI (inhalation aerosol)
Number of subjects: 154
Study 10486466 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone 24 hours before gonadotropin-releasing hormone agonist therapy
Number of subjects: 117
Study 10486466 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist alone
Number of subjects: 117
Study 8986438 — intervention group
Group type: EXPERIMENTAL
Intervention: pCMV-CFTR-DOTAP
Number of subjects: 0
Study 8986438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8986438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal potential difference measurements
Number of subjects: 0
Study 8986438 — intervention group
Group type: EXPERIMENTAL
Intervention: SPO fluorescence assay for halide ion conductance
Number of subjects: 0
Study 1876434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal column stimulation (DCS)
Number of subjects: 0
Study 1876434 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 29943804 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone catheter
Number of subjects: 534
Study 29943804 — intervention group
Group type: COMPARATOR
Intervention: Latex catheter
Number of subjects: 534
Study 29021299 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR standard dose (2 108 CFU)
Number of subjects: 150
Study 29021299 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR high dose (2 109 CFU)
Number of subjects: 150
Study 29021299 — intervention group
Group type: COMPARATOR
Intervention: Shanchol inactivated cholera vaccine (two doses)
Number of subjects: 150
Study 29021299 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR high dose
Number of subjects: 150
Study 27231129 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of chromosome Y (LOY) in blood cells
Number of subjects: 746
Study 23875876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSC) from concentrated bone marrow aspirate admixed to the bone graft material
Number of subjects: 7
Study 23875876 — intervention group
Group type: COMPARATOR
Intervention: Pure bovine bone material
Number of subjects: 7
Study 22111662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone pretreatment
Number of subjects: 0
Study 22111662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone pretreatment
Number of subjects: 0
Study 22111662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 19252811 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 2 years
Number of subjects: 208
Study 19252811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 17086406 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningiomas
Number of subjects: 29
Study 15243722 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS (impulse pattern: continuous at 80 Hz; intensity: 10‐30 mA)
Number of subjects: 66
Study 15243722 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture‐like TENS (impulse pattern: burst at 2 Hz; intensity: 15‐50 mA)
Number of subjects: 66
Study 15243722 — intervention group
Group type: COMPARATOR
Intervention: Sham control (stimulation started at 1 mA, increased to no more than 10 mA)
Number of subjects: 66
Study 12368396 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised AGP (alpha(1)-acid glycoprotein)
Number of subjects: 418
Study 12368396 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised CRP (C-reactive protein) and AGP
Number of subjects: 418
Study 12368396 — intervention group
Group type: COMPARATOR
Intervention: Infants without acute phase response
Number of subjects: 418
Study 9637744 — intervention group
Group type: COMPARATOR
Intervention: HTRIG/placebo
Number of subjects: 64
Study 9637744 — intervention group
Group type: COMPARATOR
Intervention: HRIG/placebo
Number of subjects: 64
Study 9637744 — intervention group
Group type: EXPERIMENTAL
Intervention: HTRIG/HDCV
Number of subjects: 64
Study 9637744 — intervention group
Group type: EXPERIMENTAL
Intervention: HRIG/HDCV
Number of subjects: 64
Study 8080307 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 31
Study 8080307 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 31
Study 8080307 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic touch placebo
Number of subjects: 31
Study 2773628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg)
Number of subjects: 31
Study 2773628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 31
Study 2773628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2773628 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 blockers (Ranitidine and Cimetidine)
Number of subjects: 31
Study 17559 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 10
Study 17559 — intervention group
Group type: COMPARATOR
Intervention: Placebo I
Number of subjects: 10
Study 17559 — intervention group
Group type: COMPARATOR
Intervention: Placebo II
Number of subjects: 10
Study 31642984 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols-enriched soya drink (2 g of phytosterol per day)
Number of subjects: 159
Study 31642984 — intervention group
Group type: COMPARATOR
Intervention: Matched soya drink without phytosterols
Number of subjects: 159
Study 30354023 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment (12 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Number of subjects: 182
Study 30354023 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term management (36 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Number of subjects: 182
Study 29216203 — intervention group
Group type: EXPERIMENTAL
Intervention: 18,000 IU (600 IU/day) of vitamin D3
Number of subjects: 70
Study 29216203 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU (2000 IU/day) of vitamin D3
Number of subjects: 70
Study 29216203 — intervention group
Group type: EXPERIMENTAL
Intervention: 120,000 IU (4000 IU/day) of vitamin D3
Number of subjects: 70
Study 29216203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25753495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise (unilateral hopping exercises) for 12 months, attending 92% of prescribed sessions.
Number of subjects: 50
Study 23030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment-education messages with well-integrated educational content
Number of subjects: 0
Study 23030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential involvement and perception of personal relevance in EE messages
Number of subjects: 0
Study 23030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic message processing
Number of subjects: 0
Study 21071096 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compounds (aripiprazole, lamotrigine, olanzapine/olanzapine-fluoxetine, quetiapine)
Number of subjects: 3369
Study 21071096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3369
Study 19700897 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD (Hepaticocholecystoduodenostomy)
Number of subjects: 20
Study 19700897 — intervention group
Group type: COMPARATOR
Intervention: CDJ (Roux-en-y choledochojejunostomy)
Number of subjects: 20
Study 19700897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 16729779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray once daily
Number of subjects: 61
Study 16729779 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium nasal spray 3 times daily
Number of subjects: 61
Study 15250789 — intervention group
Group type: EXPERIMENTAL
Intervention: Context related to athlete or student roles
Number of subjects: 0
Study 15250789 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-related contexts (prisoner, churchgoer, factory worker)
Number of subjects: 0
Study 15250789 — intervention group
Group type: EXPERIMENTAL
Intervention: Role cues (lawyer or prisoner) within the same prison context
Number of subjects: 0
Study 11174592 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amoxicillin (3 g per mouthwash rinse)
Number of subjects: 36
Study 11174592 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 36
Study 11174592 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis with oral amoxicillin (3 g in a single dose)
Number of subjects: 36
Study 9265424 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic catheter (chlorhexidine and silver sulfadiazine)
Number of subjects: 158
Study 9265424 — intervention group
Group type: COMPARATOR
Intervention: Control catheter (standard triple-lumen polyurethane catheter)
Number of subjects: 158
Study 8324872 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 12
Study 8324872 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2
Number of subjects: 12
Study 8324872 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2
Number of subjects: 12
Study 8324872 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 150 mg/m2
Number of subjects: 12
Study 8324872 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 75 mg/m2 vs 150 mg/m2
Number of subjects: 12
Study 3553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy
Number of subjects: 94
Study 3553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose levodopa-carbidopa therapy
Number of subjects: 94
Study 31150439 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 31150439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28857520 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine
Number of subjects: 85
Study 28857520 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 2% lidocaine
Number of subjects: 85
Study 26494348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 132
Study 26494348 — intervention group
Group type: COMPARATOR
Intervention: Conventional Restorations (CR)
Number of subjects: 132
Study 23714324 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 315
Study 23714324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 21813135 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccination with prior nasopharyngeal carriage of serotypes 6B, 19F, or 23F
Number of subjects: 0
Study 21813135 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccination with prior 19F carriage
Number of subjects: 0
Study 21813135 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccination with prior 23F carriage
Number of subjects: 0
Study 21813135 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of serotypes 6B, 19F, and 23F
Number of subjects: 0
Study 20175430 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration (LD) ergometer cycling exercise (90 min)
Number of subjects: 21
Study 20175430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI) cycling (85% of VO2(max))
Number of subjects: 21
Study 20175430 — intervention group
Group type: COMPARATOR
Intervention: Continuous (CON) cycling
Number of subjects: 21
Study 16684199 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual and storytelling pamphlets
Number of subjects: 113
Study 15219176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 microg twice daily via DISKUS
Number of subjects: 365
Study 15219176 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide/albuterol 36/206 microg four times daily via metered‐dose inhaler
Number of subjects: 365
Study 15219176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 365
Study 11201511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combined oral 17beta-estradiol norethisterone acetate
Number of subjects: 30
Study 9448650 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmastoid galvanic stimulation
Number of subjects: 0
Study 9448650 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cathodal stimulation
Number of subjects: 0
Study 9448650 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral anodal stimulation
Number of subjects: 0
Study 9448650 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar stimulation on the side of previous vestibular nerve section
Number of subjects: 0